<?xml version="1.0" encoding="UTF-8"?>
<p id="Par33">Although the results of initial treatment for childhood HL and ALCL are favorable, it is necessary to arrange treatment for patients with relapse or refractory. Targeted lymphoma therapy, using an anti-CD30 antibody, provides an innovative treatment modality for specific lymphomas, particularly HL and ALCL.</p>
